Categories
Change Password!
Reset Password!
Intravenous magnesium can be considered as first parental treatment option in migraine patients, considering its efficacy in regulating cerebral blood flow and pain transmission.
According to a recently published retrospective analysis in the Journal of Clinical Neurology and Neurosurgery, intravenous (IV) Magnesium therapy provides significant positive outcomes in relieving pain within patients suffered from status migraine.
A total of 234 migraineurs who obtained IV magnesium as a headache abortive were assessed retrospectively. If necessary, additional intramuscular (IM) injections for refractory pain (sumatriptan, dihydroergotamine, ketorolac, dexamethasone) or nausea (metoclopramide, prochlorperazine, ondansetron) were delivered. Self-reported pain levels were measured by applying an 11-point numeric pain rating scale immediately before and following the procedure.
The participants are predominantly females. Thirty-six participants suffered from migraine with aura. After administrating magnesium, overall pain scores were declined from 5.46±2.39 to 3.56 ± 2.75. A total of 127 patients showed clinically significant pain decrease (≥ 30%). One hundred and four patients didn't need supplementary intramuscular (IM) medicines for pain; showed a pain reduction from 4.76 ± 2.41 to 2.95 ± 2.70 and 59% of these patients attained ≥ 30% pain reduction. Participants with less severe pain exhibited a better response as compared to the participants with more severe pain. Hence, IV magnesium may be beneficial as a first-line cost-effective regimen for status migraine management.
Clinical Neurology and Neurosurgery
Experiences of an outpatient infusion center with intravenous magnesium therapy for status migrainosus.
Fanny Xu et al.
Comments (0)